semaglutide compounding fda news Proposes Ban on Bulk for Semaglutide, Tirzepatide, and Liraglutide FDA Warns Against Using Compounded

A meta-analysis by Han et al

These medications provide substantial advantages for weight loss and metabolic control but also produce multiple skin-related side effects

Peptides are long, delicate chains of amino acids

The idea that it penetrates skin effectively enough to influence GLP-1 production systemically is, at best, unproven

Possible options include requiring a sub-study on a representative population of ethnically identical or similar patient groups as part of the product marketing authorization and/or mandatory post-launch real-world data collection allowing assessment of product safety and efficacy in local populations

Some people may notice diarrhea more during dose increases, while others experience it throughout treatment